GlassScriptPhysician profile
Todd D Hultman
NPI 1184669806
$742.06
in general payments reported to CMS, 2019-2025
23 companies · $613 in 2025
The $613 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.32 · 2023: $23.49 · 2024: $92.31 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $88.01 | 2024-2025 | |
| Janssen Biotech, INC. | $70.75 | 2024-2025 | Talvey, Tecvayli, Erleada |
| Daiichi Sankyo INC. | $66.59 | 2025 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $61.75 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $55.25 | 2024-2025 | Lynparza, Enhertu |
| Jazz Pharmaceuticals INC. | $49.99 | 2025 | |
| Springworks Therapeutics, INC. | $36.61 | 2025 | Ogsiveo |
| Genzyme Corporation | $32.46 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.41 | 2025 | Fruzaqla |
| Genmab U.S., INC. | $23.49 | 2023 | Epkinly |
| Exelixis INC. | $22.73 | 2025 | Cabometyx |
| Geron Corporation | $21.27 | 2025 | Rytelo |
| Tersera Therapeutics LLC | $20.79 | 2025 | Zoladex |
| Novocure INC. | $19.56 | 2025 | Optune Lua (Novottf-200t) |
| Merck Sharp & Dohme LLC | $19.21 | 2025 | Keytruda, Welireg, Keytruda Qlex |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $18.34 | 2024 | Xpovio |
| Incyte Corporation | $17.93 | 2025 | Monjuvi, Zynyz |
| Eisai INC. | $16.98 | 2025 | |
| Pfizer INC. | $16.32 | 2025 | |
| Lilly USA, LLC | $15.57 | 2025 | Jaypirca, Verzenio |
| Genentech USA, INC. | $15.26 | 2025 | Polivy |
| Pharmacosmos Therapeutics INC. | $14.47 | 2025 | Monoferric |
| Glaxosmithkline, LLC. | $13.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Hultman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.